C4 Therapeutics Inc. (CCCC)
NASDAQ: CCCCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CCCC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $325.67M
- EPS (TTM)
- -$0.63
- Dividend yield
- None
- 52-week range
- 1.69 – 5.17
- Day range
- 2.32 – 2.55
- Volume / Avg
- 3.63M / 2.57M
- Beta
- —
- Shares outstanding
- 131.32M
52-week range
CCCC stock today
On Nov 20, CCCC ended the session at $2.48, adding $0.04 (1.64%), versus the S&P 500's 3.70% decline. At this level, CCCC sits in the middle of its 52-week range of $1.69 to $5.17: 52.0% below the high, set on Jun 30, 2026 and 46.7% above the low. CCCC is up 29.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.6%.
C4 Therapeutics has posted a net loss over the last twelve months (EPS of -$0.63), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About C4 Therapeutics
Company profileC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Andrew J. Hirsch M.B.A.
- Headquarters
- Watertown, MA
- Employees
- 104
- IPO year
- 2020
- Website
- c4therapeutics.com
Financial highlights
Full financialsIn fiscal 2025, C4 Therapeutics generated $35.9 million in revenue, up 1.0% from fiscal 2024, its 2nd consecutive year of revenue growth. C4 Therapeutics reported a net loss of $105.0 million, compared with a loss of $105.3 million a year earlier. Operating margin was -320.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $35.95M | $35.58M | $20.76M | $31.10M | $45.78M |
| Growth | +1.02% | +71.44% | -33.25% | -32.08% | — |
| Net income | $-104.99M | $-105.32M | $-132.49M | $-128.18M | $-83.89M |
| EPS (diluted) | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$12.50+404.03%
- Strong buy 2
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.16 vs $-0.20
- Surprise
- +20.00%
CCCC news
All CCCC news- C4 Therapeutics Reports Third Quarter 2026 Financial ResultsNasdaq
- C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire
- C4 Therapeutics to Participate in Upcoming November Investor ConferencesGlobeNewswire
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue DegradersGlobeNewswire
C4 Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLBTSL Science Holding Limited | 0.55 | -3.36% | $308.42M | vs CCCC |
| XFORX4 Pharmaceuticals Inc. | 3.00 | +1.35% | $306.34M | vs CCCC |
| TRXBTRex Bio Inc. | 10.32 | +6.12% | $296.95M | vs CCCC |
| ALECAlector Inc. | 2.34 | +1.52% | $347.63M | vs CCCC |
| DTILPrecision BioSciences Inc. | 7.40 | +7.09% | $282.46M | vs CCCC |
| AGENAgenus Inc. | 5.97 | -2.77% | $270.12M | vs CCCC |
| KYTXKyverna Therapeutics Inc. | 4.26 | -2.52% | $269.33M | vs CCCC |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs CCCC |
Indexes, lists and sector
C4 Therapeutics stock FAQ
What is C4 Therapeutics's stock price today?
CCCC last traded at $2.48 as of Nov 20, 4:00 PM EST, up 1.64% on the day. Prices are delayed at least 15 minutes.
Who is C4 Therapeutics's CEO?
Mr. Andrew J. Hirsch M.B.A. is the chief executive officer of C4 Therapeutics Inc., which has about 104 employees.
What is the CCCC 52-week high?
The 52-week high for CCCC is $5.17 and the 52-week low is $1.69. The stock is currently 52.0% below its high.